Intercept Pharmaceuticals Total Revenue

Intercept Pharmaceuticals posts a total revenue of $290M as of September 2023. That compares with $330M in the prior-year period — down 12.7% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Intercept Pharmaceuticals's total revenue was $330M. The latest reading is $290M — a 12.7% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Intercept Pharmaceuticals's $290M is lower that level. That is roughly 99.7% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Intercept Pharmaceuticals's financial statement story. At $290M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ICPT's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Intercept Pharmaceuticals's other metric pages and overview cover the third.